Pfizer has issued updated information on the availability of Bicillin L-A (penicillin G benzathine injectable suspension) and Bicillin C-R (penicillin G benzathine and penicillin G procaine injectable suspension).
Due to a manufacturing delay, there has been a supply interruption of Bicillin L-A. Pfizer has issued new dates for anticipated delivery of the drug:
- Pediatric 600,000 Units/mL PFS: Feb 2017
- 1.2 mU/2mL PFS: Dec 2016
- 2.4 mU/4mL PFS: Dec 2016
In April, the Centers for Disease Control and Prevention (CDC) recommended that until the normal stock of Bicillin L-A is available, clinicians should consider prioritizing Bicillin L-A for the treatment of syphilis especially in pregnant women infected with or exposed to syphilis. Pfizer is recommending that prioritization continue during this supply interruption.
In addition, the anticipated delivery dates for Bicillin C-R have also been updated:
- 1.2 mU/2mL PFS: Jan 2017
- Pediatric 1.2 mU/2mL PFS: Jan 2017
- 900/300 Pediatric 1.2mU/2mL PFS: Jan 2017
Bicillin L-A is a penicillinase-sensitive penicillin indicated for susceptible infections, including mild to moderate upper respiratory strep infections and syphilis. It is also indicated as follow-up prophylaxis of rheumatic heart disease and acute glomerulonephritis. Bicillin C-R is indicated to treat susceptible moderately severe infections including respiratory, skin and soft tissue, erysipelas, scarlet fever and otitis media.
Pfizer is working closely with the Food and Drug Administration (FDA) to resolve the supply issue for these critical drugs.
For more information visit FDA.gov.